Efficient and Accurate Modeling of Conformational Transitions in Proteins: The Case of c-Src Kinase.

The theoretical computational modeling of large conformational transitions occurring in biomolecules still represents a challenge. Here, we present an accurate "in silico" description of the activation and deactivation mechanisms of human c-Src kinases, a fundamental process regulating several crucial cell functions. Our results clearly show that by applying an efficient and automated algorithm able to drive the molecular dynamics (MD) sampling along the pathway between the two c-Src conformational states-the active state and the inactive state-it is possible to accurately describe, at reduced computational costs, the molecular mechanism underlying these large conformational rearrangements. This procedure, combining the MD simulations with the sampling along the well-defined principal motions connecting the two conformational states, allows to provide a description well beyond the present computational limits, and it is easily applicable to different systems where the structures of both the initial and final states are known.

[1]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[2]  G. Martin,et al.  The road to Src , 2004, Oncogene.

[3]  Sevgi Irtegun,et al.  Deregulation of c‐Src tyrosine kinase and its downstream targets in pre‐eclamptic placenta , 2017, The journal of obstetrics and gynaecology research.

[4]  R. Roskoski,et al.  Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. , 2015, Pharmacological research.

[5]  Andrew E. Torda,et al.  Local elevation: A method for improving the searching properties of molecular dynamics simulation , 1994, J. Comput. Aided Mol. Des..

[6]  Z. Zhao,et al.  A widely expressed human protein-tyrosine phosphatase containing src homology 2 domains. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Michael J. Eck,et al.  Three-dimensional structure of the tyrosine kinase c-Src , 1997, Nature.

[8]  Elif Ozkirimli,et al.  Src kinase activation: A switched electrostatic network , 2006, Protein science : a publication of the Protein Society.

[9]  E. Altmann,et al.  N(7)-substituted-5-aryl-pyrrolo[2,3-d]pyrimidines represent a versatile class of potent inhibitors of the tyrosine kinase c-Src. , 2002, Mini reviews in medicinal chemistry.

[10]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[11]  Valentina Tozzini,et al.  Coarse-grained models for proteins. , 2005, Current opinion in structural biology.

[12]  Diwakar Shukla,et al.  Transition path theory analysis of c-Src kinase activation , 2016, Proceedings of the National Academy of Sciences.

[13]  B. Druker,et al.  Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.

[14]  D. Wheeler,et al.  The role of Src in solid tumors. , 2009, The oncologist.

[15]  S. Dehm,et al.  SRC gene expression in human cancer: the role of transcriptional activation. , 2004, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[16]  R. Roskoski,et al.  Src protein-tyrosine kinase structure and regulation. , 2004, Biochemical and biophysical research communications.

[17]  T. Mulhern,et al.  Tyrosine 416 Is Phosphorylated in the Closed, Repressed Conformation of c-Src , 2013, PloS one.

[18]  M. Guarino Src signaling in cancer invasion , 2010, Journal of cellular physiology.

[19]  Grubmüller,et al.  Predicting slow structural transitions in macromolecular systems: Conformational flooding. , 1995, Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics.

[20]  Dihua Yu,et al.  Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. , 2012, Trends in pharmacological sciences.

[21]  Sheila M. Thomas,et al.  Cellular functions regulated by Src family kinases. , 1997, Annual review of cell and developmental biology.

[22]  Benoît Roux,et al.  Src Kinase Conformational Activation: Thermodynamics, Pathways, and Mechanisms , 2008, PLoS Comput. Biol..

[23]  D. van der Spoel,et al.  GROMACS: A message-passing parallel molecular dynamics implementation , 1995 .

[24]  H. Varmus,et al.  Association of the amino‐terminal half of c‐Src with focal adhesions alters their properties and is regulated by phosphorylation of tyrosine 527. , 1994, The EMBO journal.

[25]  D. Fabbro,et al.  SRC family kinases: potential targets for the treatment of human cancer and leukemia. , 2003, Current pharmaceutical design.

[26]  V. Pande,et al.  Activation pathway of Src kinase reveals intermediate states as novel targets for drug design , 2014, Nature Communications.

[27]  Benoît Roux,et al.  Locking the active conformation of c-Src kinase through the phosphorylation of the activation loop. , 2014, Journal of molecular biology.

[28]  Hiroto Yamaguchi,et al.  Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation , 1996, Nature.

[29]  C. Baldari,et al.  SRC family kinases as potential therapeutic targets for malignancies and immunological disorders. , 2008, Current medicinal chemistry.

[30]  Giovanni Chillemi,et al.  Modeling conformational transitions in kinases by molecular dynamics simulations: achievements, difficulties, and open challenges , 2014, Front. Genet..

[31]  H J Berendsen,et al.  An efficient method for sampling the essential subspace of proteins. , 1996, Journal of biomolecular structure & dynamics.

[32]  M. Parrinello,et al.  Canonical sampling through velocity rescaling. , 2007, The Journal of chemical physics.

[33]  Andrea Amadei,et al.  Molecular mechanisms of activation in CDK2 , 2014, Journal of biomolecular structure & dynamics.

[34]  R. Dror,et al.  Improved side-chain torsion potentials for the Amber ff99SB protein force field , 2010, Proteins.

[35]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[36]  K. Gibson,et al.  ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. , 2002, Cancer research.

[37]  S. Harrison,et al.  Crystal structures of c-Src reveal features of its autoinhibitory mechanism. , 1999, Molecular cell.

[38]  W. Miller,et al.  Processive phosphorylation: mechanism and biological importance. , 2007, Cellular signalling.